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Influence of Diabetes Mellitus on the Endovascular
Treatment of Abdominal Aortic Aneurysms
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EUROSTAR Collaborators
EUROSTAR Data Registry Centre, Department of Vascular Surgery, Catharina Hospital,
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l l
Purpose: To investigate the influence of diabetes mellitus on outcome after endovascular
abdominal aortic aneurysm (AAA) repair.
Methods: Of 6017 patients enrolled in the EUROSTAR registry after undergoing endovas-
cular AAA repair between May 1994 and December 2003, 731 (12%) had diabetes mellitus
(690 men; mean age 72 years, range 37–100). Patient demographics, risk factors, aneurysm
morphology, operative and procedural details, complications, major events, and regular
follow-up information were compared. The relationships of complications and events to
diabetes mellitus, which were tested with multivariate logistic regression analysis and Cox
proportional hazards modeling, are expressed as odds ratios (OR) and hazard rates (HR)
with 95% confidence intervals (CI). Survival was compared with life-table analysis.
Results: A significantly higher risk of device-related complications was observed in diabetic
patients (8% versus 6%, p,0.049; OR 1.35, 95% CI 1.00 to 1.82). The greatest difference in
the groups was in mortality, which was significantly higher in the diabetic population (13%)
compared to the nondiabetic patients (10%, p,0.039; OR 1.27, 95% CI 1.01 to 1.59). Deaths,
which occurred at a higher frequency within the 30-day perioperative period in diabetic
patients, were primary due to cardiac complications. Insulin-controlled type 2 diabetic pa-
tients had significantly lower rates of early and late endoleaks and secondary interventions
than diet-controlled type 2 diabetics (p50.002, p50.0001, and p50.0008, respectively) and
nondiabetic patients (p50.002, p50.0005, and p50.0025, respectively). The cumulative sur-
vival after 48 months did not differ significantly: 74% in diabetics and 79% in the population
without diabetes.
Conclusions: Patients with diabetes mellitus had a significantly higher early mortality rate
after EVAR, but their long-term survival was similar to nondiabetic patients.
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Endovascular aneurysm repair (EVAR) has be-
come increasingly common for the treatment
of abdominal aortic aneurysm (AAA). This
minimally invasive approach is of particular
benefit to patients with coexistent diseases
who would be at high risk for conventional
surgery.1,2 Early and midterm success of en-
dovascular AAA treatment has been docu-
mented extensively in a number of articles.3–6
Recently, the early benefits versus open sur-
gery (lower 30-day morbidity/mortality and
reduced hospital stay) were confirmed in two
randomized clinical trials.7,8
Diabetes mellitus has not been widely as-
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sessed as a comorbid factor that might im-
pact the risk or outcome of EVAR. Diabetes is
associated with accelerated rates of mortality,
particularly from cardiovascular causes, and
several chronic diseases, such as renal and
peripheral occlusive diseases.9 These comor-
bidities may increase the risk of open aneu-
rysm repair, so it may be advantageous for
diabetic patients with AAA to undergo EVAR.
In this report, we investigate if patients with
diabetes mellitus had different EVAR outcome
than nondiabetics.
METHODS
Study Design
In July 1996, the EUROSTAR project was es-
tablished with the objective of collecting and
analyzing various aspects of endovascular
AAA treatment. Data from patients operated
before the start of the registry were retrieved
retrospectively from hospital notes and pa-
tient records. Patient demographics, risk fac-
tors, aneurysm morphology, operative and
procedural details, incidence of complications
and major events (death, rupture, and con-
version to open repair), and regular follow-up
information were collected on standardized
EUROSTAR Case Record Forms. The Ameri-
can Society of Anesthesiologists (ASA) risk
classification and the Society for Vascular
Surgery (SVS) risk score10 were used to rep-
resent the patient risk profile. In the latter, risk
scores of 1 and 2 indicated diet-controlled
(oral hypoglycemic agent) or insulin-con-
trolled type 2 diabetes, respectively; type 1 di-
abetes was indicated by a risk score of 3.
Intraoperative complications encompassed
device-related sequelae, procedural failure,
and arterial complications. Postoperative (in-
hospital) complications were grouped into
systemic, procedure- and device-related, and
access site/lower limb. Endoleaks discovered
at the completion angiogram were also in-
cluded in the 30-day complication assess-
ment. Late complications included endoleaks,
kinking, thrombosis, and migration occurring
after 30 days. Follow-up examinations were
performed at 1, 3, 6, 12, 18, and 24 months
and yearly thereafter.15
Patient Population
Between May 1994 and December 2003,
6017 patients underwent endovascular AAA
repair in 163 European centers (Appendix). Of
these, 731 patients (690 men; mean age 72
years, range 37–100) had diabetes mellitus: 21
patients with type 1, 505 with diet-controlled
type 2, and 205 with insulin-controlled type 2.
Data Analysis
Data were recorded on a computerized da-
tabase. Odds ratios (OR) with 95% confidence
intervals (CI) were calculated for time-indepen-
dent variables with multivariate logistic regres-
sion analysis, while hazard rates (HR) were cal-
culated using the Cox proportional hazards
model for time-dependent characteristics.
Both tests were used to test associations be-
tween complications and diabetes. The mod-
els were adjusted for patient age, sex, ASA
classification, SVS risk factors, obesity, and un-
fitness for traditional open surgery or general
anesthesia. In the Cox proportional hazard
model for follow-up events, the immediate fail-
ures, patients lost to follow-up, and event-free
observations were censored. Analyses were
first performed for diabetic versus nondiabetic
patients, and then the type 2 diabetic popula-
tion was categorized as diet-controlled (oral
hypoglycemic agent) versus insulin-controlled
patients. Life-table analyses and Kaplan-Meier
survival estimates were used to analyze sur-
vival. Statistical significance was set at p,0.05.
Data analyses were performed with SAS sta-
tistical software (version 8.0; SAS Institutes,
Cary, NC, USA).
RESULTS
The diabetic population had significantly
higher proportions of several risk factors (Ta-
ble 1), including hypertension (76% versus
61%), hyperlipemia (25% versus 15%), im-
paired cardiac function (41% versus 30%), ca-
rotid disease (11% versus 5%), renal disease
(33% versus 17%), poor pulmonary status
(25% versus 18%), and obesity (39% versus
24%). Owing to the greater preponderance of
ASA class $3 risk (p,0.0001), diabetic pa-
tients were considered significantly more un-
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TABLE 1
Patient Demographics
Diabetics
n5731
Nondiabetics
n55286
Men 690 (94.39%) 4933 (93.32%)
Mean age, y (range) 71.9 (37–100) 71.7 (28–100)
Age .70 y 451 (61.70%) 3213 (60.82%)
ASA 3* 493 (67.44%) 2640 (49.94%)
SVS risk
Smoking 196 (26.81%) 1286 (24.33%)
Hypertension* 555 (75.92%) 3208 (60.69%)
Hyperlipemia* 183 (25.03%) 814 (15.40%)
Cardiac status* 299 (40.90%) 1560 (29.51%)
Carotid disease* 79 (10.81%) 268 (5.07%)
Renal status* 238 (32.56%) 889 (16.82%)
Pulmonary status* 183 (25.03%) 976 (18.46%)
Indication for EVAR
Previous laparotomy* 243 (33.24%) 1414 (26.79%)
Obesity* 286 (39.12%) 1240 (23.50%)
Unfit for open procedure* 222 (30.37%) 1111 (21.07%)
Unfit for general anesthesia* 100 (13.74%) 360 (6.83%)
Max AAA diameter .60 mm 224 (31.33%) 1488 (28.81%)
l l
ASA: American Society of Anesthesiologists, SVS: Society for Vascular Surgery.
* Significant difference between diabetic and nondiabetic patients (p,0.0001).
fit for open surgery and general anesthesia
(p,0.0001).
Device-related complications appeared sig-
nificantly more often in diabetic patients (8%
versus 6%, p,0.049) than in nondiabetics (OR
1.35, 95% CI 1.00 to 1.82) (Table 2). Arterial
complications, in particular, occlusion of the
renal artery, occurred more frequently in pa-
tients with diabetes (1.1% versus 0.3%,
p,0.010; OR 3.21, 95% CI 1.31 to 7.84). The
30-day mortality rate in the diabetic group
(4%) was significantly higher than in the non-
diabetic patients (2%, p,0.024; OR 1.67, 95%
CI 1.07 to 2.61). There was no difference in
early conversion or rupture rates. The higher
mortality in the diabetic population was
caused predominantly by cardiac complica-
tions (Table 3). Additional analyses of type 2
diabetics (Table 4) demonstrated a signifi-
cantly lower proportion of early endoleaks in
insulin-controlled (8%) compared to diet-con-
trolled patients (17%, p,0.0023) and the non-
diabetic (16%, p,0.0021) cohort.
Over a mean follow-up of 19.36618.88
months (range 0–96), 59 patients were lost to
follow-up (51 [1.0%] nondiabetics and 8
[1.1%] in the diabetic subgroup). Follow-up
was complete in 70% of the population (Table
5). Different types of endoleaks occurred in
similar proportions in diabetic and nondia-
betic patients, as did kinking, stenosis, throm-
bosis, and migration. Late death occurred at
comparable rates (both 9%). However, overall
mortality was significantly higher in the dia-
betic population (13%) compared to the non-
diabetic patients (10%, p,0.039; OR 1.27, 95%
CI 1.01 to 1.59). No differences were found be-
tween the groups in late conversion or rup-
ture rates. The cumulative survival rates after
48 months did not differ significantly: 74% in
diabetics and 79% in the population without
diabetes (Figure).
Further analysis of type 2 diabetic patients
(Table 6) revealed that insulin-controlled pa-
tients had significantly fewer endoleaks (8%
versus 20% [p50.0001] and 18% [p50.0005])
and secondary interventions (4% versus 12%
[p50.0008] and 11% [p50.0025]) compared to
diet-controlled and nondiabetic patients, re-
spectively.
DISCUSSION
Diabetes mellitus is part of a complex of risk
factors for cardiovascular disease that features
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TABLE 2
Early (30-Day) Complications
Diabetic
Patients
n5731
Nondiabetic
Patients
n55286
Adjusted
Odds Ratio 95% CI
Intraoperative
Device-related* 58 (7.96%) 338 (6.41%) 1.35 1.00 to 1.82
Failed procedure 17 (2.33%) 90 (1.71%) 1.37 0.79 to 2.35
Arterial 36 (4.94%) 201 (3.81%) 1.27 0.87 to 1.85
Thrombus/emboli 2 (0.38%) 36 (0.68%) 0.62 0.19 to 2.08
Occluded renal artery* 8 (1.10%) 16 (0.30%) 3.21 1.31 to 7.84
In-Hospital
Systemic 91 (12.48%) 681 (12.92%) 0.85 0.67 to 1.08
Procedure/device-related 26 (3.57%) 138 (2.62%) 1.46 0.94 to 2.26
Access/lower limb 62 (8.50%) 378 (7.17%) 1.19 0.88 to 1.59
Endoleak 105 (14.36%) 864 (16.35%) 0.87 0.70 to 1.10
Type I (Proximal) 22 (3.01%) 160 (3.03%) 0.91 0.57 to 1.46
Type I (Distal) 15 (2.05%) 125 (2.36%) 0.88 0.51 to 1.53
Type II 51 (6.97%) 466 (8.82%) 0.86 0.63 to 1.17
Type III 12 (1.64%) 125 (2.36%) 0.66 0.36 to 1.22
Early death* 29 (4.37%) 102 (2.11%) 1.67 1.71 to 2.61
Early conversion 13 (1.81%) 62 (1.20%) 1.57 0.84 to 2.95
Early rupture 0 1 (0.02%) — —
l l
Adjusted for patient age, sex, ASA classification, SVS risk factors, obesity, and unfitness
for traditional open surgery or general anesthesia.
CI: confidence interval.
* Significant difference between the diabetic and nondiabetic patients (p,0.05).
l l
TABLE 3
Cause of Early Mortality
Diabetic
Patients
n5731
Nondiabetic
Patients
n55286
Cardiac 14 (48.28%) 29 (28.43%)
Pulmonary 5 (17.24%) 12 (11.76%)
Renal 1 (3.45%) 2 (1.96%)
Multiorgan failure 1 (3.45%) 18 (17.65%)
Sepsis 2 (6.90%) 13 (12.75%)
Other/unknown 6 (20.69%) 26 (25.49%)
l l
FigurelLife-table analysis of survival for diabetic
versus nondiabetic EVAR patients.
glucose intolerance, insulin resistance, hyper-
insulinemia, increased very-low-density lipo-
proteins and triglycerides, decreased high-
density lipoproteins, and hypertension.
Diabetes has a considerable influence on the
vascular condition of patients. Indeed, in our
series, a greater proportion of the diabetic
population was considered unfit for open sur-
gery. They suffered more often from hyperten-
sion, hyperlipemia, and impaired cardiac and
renal function than the nondiabetic study
group.
However, limited information is available
with regard to the effect of diabetes on EVAR.
Rayan et al.11 investigated diabetes as a risk
factor for patients undergoing open AAA re-
pair who enrolled in the Vascular Surgery
Registry. Proportionally higher postoperative
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TABLE 4
Early Complications: Diet vs. Insulin-Controlled Type 2 Diabetics
Diet-Controlled
n5505
Insulin-
Controlled
n5205
Adjusted
Odds Ratio 95% CI
Intraoperative
Device-related 46 (9.13%)* 11 (5.39%) 0.57 0.29 to 1.12
Failed procedure 12 (2.38%) 4 (1.96%) 0.82 0.26 to 2.57
Arterial 23 (4.56%) 11 (5.39%) 1.19 0.57 to 2.49
Thrombus/emboli 2 (0.40%) 1 (0.49%)
Occluded renal artery 6 (1.19%)* 2 (0.98%) 0.82 0.16 to 4.11
In-Hospital
Systemic 60 (11.90%) 30 (14.71%) 1.28 0.80 to 2.05
Procedure/device-related 21 (4.17%)* 5 (2.45%) 0.58 0.21 to 1.55
Access/lower limb 41 (8.13%) 19 (9.31%) 1.16 0.66 to 2.05
Endoleak† 87 (17.23%) 17 (8.29%)‡ 0.43 0.25 to 0.75
Type I (Proximal)† 20 (3.96%) 1 (0.49%)‡ 0.12 0.02 to 0.89
Type I (Distal) 14 (2.77%) 1 (0.49%) 0.17 0.02 to 1.31
Type II 40 (7.92%) 10 (4.88%) 0.60 0.29 to 1.21
Type III 10 (1.98%) 2 (0.98%) 0.49 0.11 to 2.25
Early death 22 (4.36%) 7 (3.41%) 0.78 0.33 to 1.85
l l
Adjusted for patient age, sex, ASA classification, SVS risk factors, obesity, and unfitness
for traditional open surgery or general anesthesia.
CI: confidence interval.
* Significant difference between the diet-controlled diabetic patients and the nondiabetic
patients (p,0.045).
† Significant difference between the diet and insulin-controlled subgroups (p,0.015).
‡ Significant difference between the insulin-controlled diabetic patients and the nondia-
betic patients (p,0.035).
l l
TABLE 5
Late Complications
Diabetic
Patients
n5731
Nondiabetic
Patients
n55286
Adjusted
Hazard
Rate 95% CI
Endoleak 119 (16.28%) 953 (18.03%) 1.05 0.87 to 1.28
Type I (proximal) 20 (2.74%) 157 (2.97%) 1.03 0.64 to 1.67
Type I (distal) 27 (3.69%) 218 (4.12%) 1.09 0.72 to 1.63
Type II 67 (9.17%) 563 (10.65%) 0.96 0.74 to 1.25
Type III 28 (3.83%) 227 (4.29%) 1.19 0.80 to 1.78
Kinked stent-graft 13 (1.91%) 183 (3.46%) 0.81 0.47 to 1.41
Stenosis/thrombosis 38 (5.20%) 281 (5.32%) 1.08 0.76 to 1.53
Graft migration 24 (3.28%) 275 (5.20%) 0.87 0.57 to 1.33
Secondary intervention 71 (9.71%) 586 (11.09%) 1.07 0.83 to 1.38
Late death 67 (9.16%) 452 (8.55%) 1.15 0.88 to 1.50
Late conversion 11 (1.50%) 118 (2.23%) 1.02 0.54 to 1.91
Late rupture 2 (0.27%) 43 (0.81%) 0.44 0.10 to 1.84
l l
Adjusted for patient age, sex, ASA classification, SVS risk factors, obesity, and unfitness
for traditional open surgery or general anesthesia.
CI: confidence interval.
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TABLE 6
Late Complications: Diet vs. Insulin-Controlled Type 2 Diabetes
Diet-
Controlled
n5505
Insulin-
Controlled
n5205
Adjusted
Hazard Rate 95% CI
Endoleak* 99 (19.60%) 16 (7.8%)† 0.35 0.20 to 0.61
Type I (proximal) 14 (2.77%) 4 (1.95%) 0.71 0.23 to 2.21
Type I (distal) 23 (4.55%) 3 (1.46%) 0.32 0.09 to 1.07
Type II* 55 (10.89%) 10 (4.88%)† 0.43 0.21 to 0.86
Type III 23 (4.55%) 5 (2.44%) 0.54 0.20 to 1.43
Kinked stent-graft 12 (2.38%) 1 (0.49%) 0.21 0.03 to 1.60
Stenosis/thrombosis 27 (5.35%) 11 (5.37%) 1.03 0.50 to 2.13
Graft migration 21 (4.16%) 3 (1.46%)† 0.35 0.10 to 1.19
Secondary intervention* 62 (12.28%) 8 (3.9%)† 0.29 0.14 to 0.63
Late death 46 (9.11%) 20 (9.76%) 1.08 0.62 to 1.87
Late conversion 10 (1.98%) 1 (0.49%) 0.24 0.03 to 1.91
Late rupture 1 (0.20%) 1 (0.49%) 2.47 0.15 to 39.69
l l
Adjusted for patient age, sex, ASA classification, SVS risk factors, obesity, and unfitness
for traditional open surgery or general anesthesia.
CI: confident interval.
* Significant difference between the diet and insulin-controlled subgroups (p,0.015).
† Significant difference between insulin-controlled diabetic patients and nondiabetic pa-
tients (p,0.025).
mortality was noticed in the diabetic popula-
tion. However, long-term cumulative survival
was identical for diabetic versus nondiabetic
patients, which we found when analyzing the
correlation between diabetes and endovas-
cular AAA repair.
In our investigation of the relationship be-
tween diabetes and EVAR, patients with dia-
betes more often experienced device-related
complications and arterial sequelae, such as
occlusion of the renal artery. The most striking
finding was the significantly higher 30-day
mortality rate (4%) in the diabetic group, which
was caused primarily by cardiac insufficiency.
However, this higher early mortality rate was
still in the 0% to 7% range reported by other
recent studies analyzing EVAR.1,5,12–14 de Vir-
gilio et al.15 compared cardiac morbidity and
mortality between conventional and endovas-
cular AAA repair, but in their study, diabetes
was not a predictive criterion for an adverse
cardiac event (p50.07).
In type 2 diabetes, insulin treatment is used
when diet, exercise, and oral agents are un-
able to establish adequate glycemic control.
The United Kingdom Prospective Diabetes
Study showed that improved glycemic con-
dition in type 2 diabetes reduced vascular and
all diabetes-related complications.16,17 Some
authors have demonstrated a relationship be-
tween the duration of diabetes and the inci-
dence of vascular complications, although the
issue is disputed by several other investiga-
tors.18–25 Type 2 diabetes mellitus was fre-
quently missed at diagnosis because hyper-
glycemia frequently was not severe enough
to provoke characteristic symptoms of dia-
betes. Nevertheless, in this stage, patients are
at increased risk of developing macrovascular
and microvascular complications.26,27 The fact
that elevated blood glucose levels may have
been present for several months or even
years before the diagnosis of type 2 diabetes
is made complicates the analyses. Hence, the
actual duration of type 2 diabetes cannot eas-
ily be estimated.
Compared to diet-controlled (oral hypogly-
cemic) or nondiabetic patients in our study,
insulin-controlled type 2 diabetics had a sig-
nificantly lower rate of endoleaks, which re-
sulted in fewer secondary interventions. The
lower incidence of endoleak in this patient
group may be explained by the impact of di-
abetes on blood vessels. Diabetes affects the
endothelial lining of arteries, causing them to
become clogged with plaque, so the aortic
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side branches, including the lumbar, inferior
mesenteric, internal iliac, and renal arteries,
become less elastic and more occlusive. In
addition, medication to help keep the blood
glucose levels within a safe range or to con-
trol diabetes-related complications, such as
high blood pressure or nephropathy (e.g., an-
giotensin-converting enzyme inhibitors or an-
giotensin II receptor blockers), may influence
the arterial condition and endoleak develop-
ment.9,28
Riambeau et al.29 analyzed the association
between comorbidity and mortality after
EVAR in patients considered unfit for open
surgery. The survival curves in patients with
poor medical condition were significantly
worse than in those with a good medical sta-
tus. However, the presence of co-existing dis-
eases in patients unfit for open surgery did
not affect the mortality rate. In our study pop-
ulation, the survival curves of diabetic and
nondiabetic patients demonstrated similar cu-
mulative survival after 4 years.
EUROSTAR, like any voluntary registry, has
its advantages and disadvantages. The main
advantages are the ability to gather a large
amount of data on a diverse patient popula-
tion in a relatively short period of time, ad-
dress upcoming questions, evaluate long-
term effectiveness, and include new devices
or improvements. Disadvantages are a lack of
randomization and double-blinding, a large
interobserver variation, and less accurate and
complete data. Nevertheless, a registry pop-
ulation normally is a good reflection of com-
mon day clinical practice.
Conclusions
Patients with diabetes had a significantly
higher 30-day mortality rate then patients
without diabetes. After a lower initial success
rate, long-term survival was similar in both
study groups. More assessment is needed to
evaluate the effect of diabetes on EVAR out-
come.
APPENDIX
EUROSTAR centers that contributed to this
study:
Austria: University Hospital, Vienna.
Belgium: ASZ and Onze Lieve Vrouwe Hos-
pital, Aalst; AZ Middelheim, St. Vincentius
Hospital, UIA, Monica Hospital/OLV/Eeuw-
feestkliniek, and St. Augustinus Hospital, An-
twerpen; AZ St. Lucas/St. Jozef, Assebroek;
Hospital Princesse Paola, Aye; Imelda Hospi-
tal, Bonheiden; AZ Klina, Brasschaat; AZ St.
Jan AV, Brugge; Hospital Erasme, Academic
Hospital VUB, Clinique de l’Europe St. Michel,
CHU Brugmann, and University Hospital St.
Luc, Brussels; CHU, Charleroi; AZ St. Blasius,
Dendermonde; AZ St. Maarten, Duffel; AZ St.
Dimpna, Geel; St. Jan Hospital, AZ St. Lucas,
and University Hospital, Genk; St. Joseph
Hospital, Gilly; Virga Jesse Hospital, Hasselt;
St. Elisabeth, Herenthals; CAZ St. Franciskus
Hospital, Heusden-Zolder; AZ Groenige, Kort-
rijk; University Hospital and Heilig Hart, Leu-
ven; Notre-Dame des Bruyeres, Lie`ge-Che-
nee; Maria Hospital, Lommel; OLV Hospital,
Mechelen; CHM CNDT, Moucron; CHRN, Na-
mur; AZ Heilige Familie, Reet; Stedelijk Hos-
pital and HHR Hart Hospital, Roeselare; St.
Trudo Hospital, St. Truiden; St. Josef Hospital,
Turnhout; St. Augustinus Hospital, Veurne; St,
Josef Hospital, Vilvoorde.
Denmark: Rigshospitalet, Copenhagen; Uni-
versity Hospital, Odense.
France: Hospital Notre Dame, Draguignan;
Clinique Mutaliste des Eaux Claires, Greno-
ble; Hospital for Cardiology, Lille; Hospital
Jeanne d’Arc and Hospital E Herriot, Lyon;
Polyclinic d’Essey, Nancy; Hospital de la De-
fense, Nanterre; Hospital Henri Mondor and
Hospital Broussais, Paris; CHU Hospital
North, St. Etienne; Institut Arnauld Tzanck, St.
Laurant du Var; Hospital Sarrus Teinturier and
Hospital de Rangueil, Toulouse.
Germany: Surgical University Clinic, Bonn;
Augusta Hospital, Du¨sseldorf; Sta¨dtischen Kli-
niken and Sankt Katharinen, Frankfurt; Uni-
versity Hospital, Freiburg; Altona General
Hospital, Hamburg; Henriettenstiftung, Han-
nover; Klinikum Kempten; Bundeswehrzen-
tral, Koblenz; Park-Krankenhaus, Leipzig; Uni-
versity Hospital, Mainz; Philipps-University,
Marburg; Kliniken Rechts der Isar, Mu¨nchen;
Pius Hospital, Oldenburg; University Hospital,
Ulm.
Greece: University Medical School, Athens.
Ireland: St. James Hospital, Dublin.
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Israel: Sheba Medical Centre, Tel Aviv.
Italy: Policlinico Monteluce, Perugia; Ospe-
dale S Giovanni, Rome.
Luxembourg: Centre Hospitalier, Luxem-
bourg.
Monaco: Centre Cardio-Thoracique, Mona-
co.
The Netherlands: Medical Centre, Alkmaar;
Academic Medical Centre, VU, and Onze
Lieve Vrouwe Gasthuis, Amsterdam; Gelre
Hospital, Apeldoorn; Rijnstate, Arnhem; Rei-
nier de Graaf Group, Delft; Medical Centre
Haaglanden Westeinde and Leijenburg Hos-
pital, The Hague; Albert Schweitzer Hospital,
Dordrecht; Catharina Hospital, Eindhoven;
Medisch Spectrum Twente, Enschede; St.
Anna Hospital, Geldrop; Academic Hospital
and Martini Hospital, Groningen; Academic
Hospital, Maastricht; St. Antonius Hospital,
Nieuwegein; CWZ Hospital and Academic
Hospital, Nijmegen; St. Clara Hospital, Dijk-
zicht Hospital, and Franciscus Gasthuis, Rot-
terdam; Elisabeth Hospital and Tweesteden
Hospital, Tilburg; University Medical Centre,
Utrecht; St. Josef Hospital, Veldhoven; Isala
Clinics Sophia, Zwolle.
Norway: Aker University Hospital and Ul-
leval Hospital, Oslo; University Hospital,
Trondheim.
Poland: L’Academie de Medicine, Lublin;
Medical University, MSWiA Hospital, and
Central Military Hospital, Warsaw.
Spain: University Hospital, Ciutat Sanitaria
i Universitaria de Bellvitge, and Hospital de la
Santa Creu i Sant Pau, Barcelona; Hospital de
Gipuzkoa, Donostia San Sebastian; Hospital
Juan Canalejo and Hospital Santa Teresa, La
Corun˜a; Hospital de Leon, Hospital Xeral
Lugo, University Hospital de la Princesa, Hos-
pital Ramon y Cajal, Fundacion Jimenez Diaz,
and University Hospital of Getafe, Madrid;
University Hospital of Navarra, Pamplona;
Hospital Clinico, Valladolid.
Sweden: University Hospital, Lund; Medical
Centre, O¨rebro.
Switzerland: Clinic for Cardiovascular Sur-
gery, Bern; Gefa¨sszentrum, Zu¨rich.
Turkey: Memorial Hospital and University
Hospital, Istanbul.
United Kingdom: Royal Hospital, Bourne-
mouth; Royal Infirmary, Bristol; Countess of
Chester Hospital, Chester; Gartnavel Hospital,
Glasgow; Royal Infirmary, Hull; Royal Univer-
sity Hospital, Liverpool; St. Mary’s Hospital,
London; Withington Hospital, Manchester;
Freeman Hospital, New Castle-Upon-Tyne.
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